心力衰竭射血分数改善的频率、预测因素与预后:基于超声心动图的注册研究
37.6%患者出现射血分数改善(HFrecEF,绝对改善≥10%),其死亡、住院、急诊就诊及心脏移植/左室辅助装置植入风险均显著低于持续性HFrEF患者。女性、年轻、房颤、癌症、高血压、较低基线EF及使用肼屈嗪与EF改善相关。
要点
- HFrecEF患者死亡风险显著低于持续性HFrEF(aHR 0.70)。
- 女性、房颤、高血压、癌症及较低基线EF预测EF改善。
- 女性HFrEF患者死亡风险低于男性(aHR 0.94)。
核心结论
- HFrecEF患者预后显著优于持续性HFrEF,且女性死亡风险低于男性。
主要发现
- 1174例(37.6%)出现HFrecEF(EF绝对改善≥10%),其EF从26.1%升至46.4%,而持续性HFrEF患者EF从30.2%降至28.6%。
- HFrecEF患者每1000患者年死亡率106 vs 164(aHR 0.70 [0.62-0.79]),全因住院300 vs 428(aHR 0.87 [0.79-0.95]),急诊就诊569 vs 799(aHR 0.88 [0.81-0.95]),心脏移植或左室辅助装置植入2 vs 10(aHR 0.21 [0.10-0.45])。
- 多变量分析显示女性(aOR 1.66 [1.40-1.96])、年轻(每十年aOR 1.16 [1.09-1.23])、房颤(aOR 2.00 [1.68-2.38])、癌症(aOR 1.52 [1.03-2.26])、高血压(aOR 1.38 [1.18-1.62])、较低基线EF(每降低1% aOR 1.07 [1.06-1.08])及使用肼屈嗪(aOR 1.69 [1.19-2.40])与EF改善≥10%相关。
- 女性HFrEF患者死亡风险低于男性(aHR 0.94 [0.88-0.99]),校正年龄、超声间隔、合并症、药物及EF是否改善后仍显著。
临床怎么用
- 识别HFrecEF预测因素(女性、年轻、房颤、高血压、癌症、较低基线EF、使用肼屈嗪)有助于风险分层。
- HFrecEF患者预后较好,但仍需关注其长期管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: To identify variables predicting ejection fraction (EF) recovery and characterize prognosis of heart failure (HF) patients with EF recovery (HFrecEF). METHODS AND RESULTS: Retrospective study of adults referred for ≥2 echocardiograms separated by ≥6 months between 2008 and 2016 at the two largest echocardiography centres in Alberta who also had physician-assigned diagnosis of HF. Of 10 641 patients, 3124 had heart failure reduced ejection fraction (HFrEF) (EF ≤ 40%) at baseline: while mean EF declined from 30.2% on initial echocardiogram to 28.6% on the second echocardiogram in those patients with persistent HFrEF (defined by <10% improvement in EF), it improved from 26.1% to 46.4% in the 1174 patients (37.6%) with HFrecEF (defined by EF absolute improvement ≥10%). On multivariate analysis, female sex [adjusted odds ratio (aOR) 1.66, 95% confidence interval (CI) 1.40-1.96], younger age (aOR per decade 1.16, 95% CI 1.09-1.23), atrial fibrillation (aOR 2.00, 95% CI 1.68-2.38), cancer (aOR 1.52, 95% CI 1.03-2.26), hypertension (aOR 1.38, 95% CI 1.18-1.62), lower baseline ejection fraction (aOR per 1% decrease 1.07 (1.06-1.08), and using hydralazine (aOR 1.69, 95% CI 1.19-2.40) were associated with EF improvements ≥10%. HFrecEF patients demonstrated lower rates per 1000 patient years of mortality (106 vs. 164, adjusted hazard ratio, aHR 0.70 [0.62-0.79]), all-cause hospitalizations (300 vs. 428, aHR 0.87 [0.79-0.95]), all-cause emergency room (ER) visits (569 vs. 799, aHR 0.88 [0.81-0.95]), and cardiac transplantation or left ventricular assist device implantation (2 vs. 10, aHR 0.21 [0.10-0.45]) compared to patients with persistent HFrEF. Females with HFrEF exhibited lower mortality risk (aHR 0.94 [0.88-0.99]) than males after adjusting for age, time between echocardiograms, clinical comorbidities, medications, and whether their EF improved or not during follow-up. CONCLUSION: HFrecEF patients tended to be younger, female, and were more likely to have hypertension, atrial fibrillation, or cancer. HFrecEF patients have a substantially better prognosis compared to those with persistent HFrEF, even after multivariable adjustment, and female patients exhibit lower mortality risk than men within each subgroup (HFrecEF and persistent HFrEF) even after multivariable adjustment.
引用
- Ghimire A, Fine N, Ezekowitz JA, et al. Frequency, predictors, and prognosis of ejection fraction improvement in heart failure: an echocardiogram-based registry study. Eur Heart J. 2019. PMID: 31280320. doi:10.1093/eurheartj/ehz233
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。